{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:16:27Z","timestamp":1791288987694,"version":"4.3.0"},"reference-count":157,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100006014","name":"College of Medicine and Health Sciences, United Arab Emirates University","doi-asserted-by":"publisher","award":["31R018"],"award-info":[{"award-number":["31R018"]}],"id":[{"id":"10.13039\/501100006014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["312M289"],"award-info":[{"award-number":["312M289"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00448","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T03:46:34Z","timestamp":1499399194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":63,"title":["Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises"],"prefix":"10.3389","volume":"8","author":[{"given":"Fedah E.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihadh","family":"Al-Gazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Al-Jasmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/8904_2012_182","article-title":"Prevalence and novel mutations of lysosomal storage disorders in united arab emirates: LSD in UAE.","volume":"10","author":"Al-Jasmi","year":"2013","journal-title":"JIMD Rep."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS ONE"},{"key":"B3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal disorders: from storage to cellular damage.","volume":"1793","author":"Ballabio","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","article-title":"Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.","volume":"87","author":"Barton","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1021\/jm101443u","article-title":"Crystal structure of \u03b2-Hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone\u2020.","volume":"54","author":"Bateman","year":"2011","journal-title":"J. Med. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1517\/14728214.2010.498580","article-title":"Emerging drugs for lysosomal storage diseases. Expert Opin.","volume":"15","author":"Beck","year":"2010","journal-title":"Emerg. Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier.","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"B9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice.","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ymgme.2014.05.009","article-title":"Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients.","volume":"112","author":"Berardi","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.6.e69","article-title":"Inborn errors of metabolism in infancy: a guide to diagnosis.","volume":"102","author":"Burton","year":"1998","journal-title":"Pediatrics"},{"key":"B13","first-page":"2623","article-title":"Protein homeostasis as a therapeutic target for diseases of protein conformation.","volume":"12","author":"Calamini","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1742-4658.2006.05181.x","article-title":"Protein-misfolding diseases and chaperone-based therapeutic approaches.","volume":"273","author":"Chaudhuri","year":"2006","journal-title":"FEBS J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1093\/hmg\/ddi259","article-title":"ER-associated protein degradation is a common mechanism underpinning numerous monogenic diseases including Robinow syndrome.","volume":"14","author":"Chen","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12035-013-8605-5","article-title":"Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on beta-hexosaminidase activity in Sandhoff fibroblasts.","volume":"50","author":"Chiricozzi","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label Phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ymgme.2011.12.012","article-title":"Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction.","volume":"105","author":"Coutinho","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/21678707.2015.1025746","article-title":"Pathogenesis, emerging therapeutic targets and treatment in sialidosis.","volume":"3","author":"d\u2019Azzo","year":"2015","journal-title":"Expert Opin. Orphan. Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/ncb0905-847","article-title":"The lysosome turns fifty.","volume":"7","author":"de Duve","year":"2005","journal-title":"Nat. Cell Biol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1042\/bj0600604","article-title":"Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue.","volume":"60","author":"de Duve","year":"1955","journal-title":"Biochem. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"15169","DOI":"10.1073\/pnas.1105639108","article-title":"Insights into Krabbe disease from structures of galactocerebrosidase.","volume":"108","author":"Deane","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3201\/eid1611.101064","article-title":"Sulfadoxine\/Pyrimethamine intermittent preventive treatment for malaria during pregnancy.","volume":"16","author":"Deloron","year":"2010","journal-title":"Emerg Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1091\/mbc.E16-01-0012","article-title":"Tay-Sachs disease mutations in HEXA target the alpha chain of hexosaminidase A to endoplasmic reticulum-associated degradation.","volume":"27","author":"Dersh","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"B26","first-page":"449","article-title":"A selective pathway for degradation of cytosolic proteins by lysosomes.","volume":"1","author":"Dice","year":"1990","journal-title":"Semin Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.","volume":"19","author":"Douillard-Guilloux","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrm1052","article-title":"Quality control in the endoplasmic reticulum.","volume":"4","author":"Ellgaard","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.bbamcr.2008.07.014","article-title":"Autophagy: a lysosomal degradation pathway with a central role in health and disease.","volume":"1793","author":"Eskelinen","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/s0076-6879(03)01069-3","article-title":"Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.","volume":"363","author":"Fan","year":"2003","journal-title":"Methods Enzymol."},{"key":"B31","first-page":"133","article-title":"Abnormal chaperone-mediated autophagy (CMA) in cardiomyocytes of a boy with Danon disease.","volume":"45","author":"Fidzianska","year":"2007","journal-title":"Folia Neuropathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1479-7364-5-3-156","article-title":"Lysosomal storage disorders: molecular basis and laboratory testing.","volume":"5","author":"Filocamo","year":"2011","journal-title":"Hum. Genomics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/emboj.2010.237","article-title":"Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders.","volume":"29","author":"Fraldi","year":"2010","journal-title":"EMBO J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/nejm200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy.","volume":"345","author":"Frustaci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders.","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease.","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","article-title":"Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.","volume":"94","author":"Giraldo","year":"2009","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/1817-1745.205623","article-title":"Sandhoff disease without hepatosplenomegaly due to hexosaminidase B gene mutation.","volume":"12","author":"Gowda","year":"2017","journal-title":"J. Pediatr. Neurosci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.mop.0000172702.33128.19","article-title":"Recent clinical progress in Gaucher disease.","volume":"17","author":"Grabowski","year":"2005","journal-title":"Curr. Opin. Pediatr."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/537S145a","article-title":"Lysosomal storage disorders.","volume":"537","author":"Grayson","year":"2016","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/09687860600967317","article-title":"Topology and endoplasmic reticulum retention signals of the lysosomal storage disease-related membrane protein CLN6.","volume":"24","author":"Heine","year":"2007","journal-title":"Mol. Membr. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/humu.21516","article-title":"Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in beta-galactosidase deficiency.","volume":"32","author":"Higaki","year":"2011","journal-title":"Hum. Mutat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1039\/c5sc00754b","article-title":"Azasugar inhibitors as pharmacological chaperones for Krabbe disease.","volume":"6","author":"Hill","year":"2015","journal-title":"Chem. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drudis.2010.08.017","article-title":"Iminosugars past, present and future: medicines for tomorrow.","volume":"16","author":"Horne","year":"2011","journal-title":"Drug Discov. Today"},{"key":"B46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/jhg.2015.61","article-title":"Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations.","volume":"60","author":"Hossain","year":"2015","journal-title":"J. Hum. Genet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.braindev.2015.07.006","article-title":"Chemical chaperone treatment for galactosialidosis: effect of NOEV on beta-galactosidase activities in fibroblasts.","volume":"38","author":"Hossain","year":"2016","journal-title":"Brain Dev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/bies.950180508","article-title":"Intracellular trafficking of lysosomal membrane proteins.","volume":"18","author":"Hunziker","year":"1996","journal-title":"Bioessays"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1194\/jlr.R048090","article-title":"Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities.","volume":"55","author":"Ingemann","year":"2014","journal-title":"J. Lipid Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/21556660.2013.827117","article-title":"Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A\/AT1001) in healthy male Japanese subjects.","volume":"2","author":"Ino","year":"2013","journal-title":"J. Drug Assess."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","article-title":"Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease.","volume":"197","author":"Ishii","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1365-2990.2002.00422.x","article-title":"Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.","volume":"28","author":"Jeyakumar","year":"2002","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B54","first-page":"55","article-title":"GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series).","volume":"8","author":"Karimzadeh","year":"2014","journal-title":"Iran J. Child Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg3493","article-title":"Molecular genetic testing and the future of clinical genomics.","volume":"14","author":"Katsanis","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102092","article-title":"The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.","volume":"9","author":"Khanna","year":"2014","journal-title":"PLoS ONE"},{"key":"B57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","article-title":"Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening.","volume":"29","author":"Kingma","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"B58","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1517\/21678707.2013.780970","article-title":"Emerging therapies and therapeutic concepts for lysosomal storage diseases.","volume":"1","author":"Kirkegaard","year":"2013","journal-title":"Expert Opin. Orphan. Drugs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe registry.","author":"Kishnani","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"B60","doi-asserted-by":"publisher","first-page":"21673","DOI":"10.1074\/jbc.274.31.21673","article-title":"Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons.","volume":"274","author":"Korkotian","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-biochem-060614-033955","article-title":"The biology of proteostasis in aging and disease.","volume":"84","author":"Labbadia","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.carres.2016.03.007","article-title":"Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease.","volume":"429","author":"Laigre","year":"2016","journal-title":"Carbohydr. Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1523\/jneurosci.6383-09.2010","article-title":"Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones.","volume":"30","author":"Lee","year":"2010","journal-title":"J. Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2174\/1567205011310040008","article-title":"Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-beta pathology in a mouse model of Alzheimer\u2019s disease.","volume":"10","author":"Li","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00018-011-0865-5","article-title":"Microautophagy: lesser-known self-eating.","volume":"69","author":"Li","year":"2012","journal-title":"Cell Mol. Life Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2013a comprehensive review of the medical literature.","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bbadis.2004.03.007","article-title":"N-Octyl-\u03b2-valienamine up-regulates activity of F213I mutant \u03b2-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease.","volume":"1689","author":"Lin","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a004507","article-title":"Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases\u2013progress and prognosis.","volume":"3","author":"Lindquist","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1111\/febs.12954","article-title":"The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations.","volume":"281","author":"Macias-Vidal","year":"2014","journal-title":"FEBS J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0925-4439(99)00074-5","article-title":"Biochemical consequences of mutations causing the GM2 gangliosidoses.","volume":"1455","author":"Mahuran","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"B72","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.pediatrneurol.2003.09.003","article-title":"The status of hematopoietic stem cell transplantation in lysosomal storage disease.","volume":"29","author":"Malatack","year":"2003","journal-title":"Pediatr. Neurol."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS ONE"},{"key":"B74","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1172\/jci115863","article-title":"An unusual splicing mutation in the HEXB gene is associated with dramatically different phenotypes in patients from different racial backgrounds.","volume":"90","author":"McInnes","year":"1992","journal-title":"J. Clin. Invest."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060026","article-title":"Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.","volume":"6","author":"Mu","year":"2008","journal-title":"PLoS Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Proteostasis regulators and pharmacologic chaperones synergize to correct protein misfolding diseases.","volume":"134","author":"Mu","year":"","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases.","volume":"134","author":"Mu","year":"","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10545-014-9701-z","article-title":"Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.","volume":"37","author":"Muntau","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"B79","first-page":"1082","article-title":"Lysosomal storage disorders and treatment.","volume":"2","author":"Murthy","year":"2010","journal-title":"Int. J. Pharm. Technol. Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/138920110790909650","article-title":"Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.","volume":"11","author":"Nagai","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B81","first-page":"25","article-title":"Penetration into and elimination from the cerebrospinal fluid of diltiazem, a calcium antagonist, in anesthetized rabbits.","volume":"36","author":"Naito","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"B82","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic gaucher disease: a pilot study.","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/0960-894X(96)00146-1","article-title":"Synthesis of potent \u03b2-D-glucocerebrosidase inhibitors: N-alkyl-\u03b2-valienamines.","volume":"6","author":"Ogawa","year":"1996","journal-title":"Bioorg. Med. Chem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.","volume":"214","author":"Okumiya","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B85","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymgme.2012.07.013","article-title":"The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis.","volume":"107","author":"O\u2019Leary","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"B86","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ymgme.2010.11.163","article-title":"Pyrimethamine increases beta-hexosaminidase A activity in patients with Late Onset Tay Sachs.","volume":"102","author":"Osher","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"B87","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/humu.20205","article-title":"Identification of mutations in the GNPTA (MGC4170) gene coding for GlcNAc-phosphotransferase alpha\/beta subunits in Korean patients with mucolipidosis type II or type IIIA.","volume":"26","author":"Paik","year":"2005","journal-title":"Hum. Mutat."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1093\/hmg\/ddr306","article-title":"Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways.","volume":"20","author":"Palmieri","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/ijmm.2012.1187","article-title":"New strategies for the treatment of lysosomal storage diseases (review).","volume":"31","author":"Parenti","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/2042018810384429","article-title":"Therapeutic approaches for lysosomal storage diseases.","volume":"8","author":"Pastores","year":"2010","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"B91","doi-asserted-by":"publisher","first-page":"29496","DOI":"10.1074\/jbc.M302964200","article-title":"Inhibition of calcium uptake via the sarco\/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.","volume":"278","author":"Pelled","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B92","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal.","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1073\/pnas.1014890108","article-title":"Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts.","volume":"108","author":"Pipalia","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B94","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"Lysosomal storage disorders: the cellular impact of lysosomal dysfunction.","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.bbamcr.2008.08.009","article-title":"Treating lysosomal storage disorders: current practice and future prospects.","volume":"1793","author":"Platt","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B96","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in pompe disease fibroblasts.","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine.","volume":"20","author":"Porto","year":"2012","journal-title":"Mol. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s11064-010-0380-3","article-title":"Secondary alterations of sphingolipid metabolism in lysosomal storage diseases.","volume":"36","author":"Prinetti","year":"2011","journal-title":"Neurochem. Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1074\/jbc.M114.612507","article-title":"Analysis of mucolipidosis II\/III GNPTAB missense mutations identifies domains of UDP-GlcNAc:lysosomal enzyme GlcNAc-1-phosphotransferase involved in catalytic function and lysosomal enzyme recognition.","volume":"290","author":"Qian","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma.","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy.","volume":"11","author":"Richter","year":"2014","journal-title":"Neurotherapeutics"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1186\/jbiol186","article-title":"Q&A: what are pharmacological chaperones and why are they interesting?","volume":"8","author":"Ringe","year":"2009","journal-title":"J. Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2165\/00003495-200767180-00005","article-title":"Treatment of lysosomal storage disorders: progress with enzyme replacement therapy.","volume":"67","author":"Rohrbach","year":"2007","journal-title":"Drugs"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.","volume":"14","author":"Ron","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B105","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1083\/jcb.201312042","article-title":"Quality control: ER-associated degradation: protein quality control and beyond.","volume":"204","author":"Ruggiano","year":"2014","journal-title":"J. Cell Biol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrm2745","article-title":"Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function.","volume":"10","author":"Saftig","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bcmd.2013.03.006","article-title":"Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease.","volume":"51","author":"Sanders","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/adc.2005.091637","article-title":"The incidence of inherited metabolic disorders in the West Midlands, UK.","volume":"91","author":"Sanderson","year":"2006","journal-title":"Arch. Dis. Child"},{"key":"B109","doi-asserted-by":"publisher","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","article-title":"Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis.","volume":"33","author":"Sandhoff","year":"2013","journal-title":"J. Neurosci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.molcel.2009.10.021","article-title":"GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis.","volume":"36","author":"Sano","year":"2009","journal-title":"Mol. Cell."},{"key":"B111","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1039\/b804606a","article-title":"Small molecule enhancers of autophagy for neurodegenerative diseases.","volume":"4","author":"Sarkar","year":"2008","journal-title":"Mol. Biosyst."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.biocel.2005.05.008","article-title":"Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher\u2019s disease.","volume":"37","author":"Schmitz","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s40265-015-0468-9","article-title":"Eliglustat: a review in gaucher disease type 1.","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"B114","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/iub.1288","article-title":"Impairment of homeostasis in lysosomal storage disorders.","volume":"66","author":"Segatori","year":"2014","journal-title":"IUBMB Life"},{"key":"B115","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nature02264","article-title":"Folding proteins in fatal ways.","volume":"426","author":"Selkoe","year":"2003","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tibs.2015.01.002","article-title":"UPR, autophagy, and mitochondria crosstalk underlies the ER stress response.","volume":"40","author":"Senft","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"B117","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2006-10-050807","article-title":"Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation.","volume":"109","author":"Sethi","year":"2007","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3565","article-title":"Signals for the lysosome: a control center for cellular clearance and energy metabolism.","volume":"14","author":"Settembre","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1194\/jlr.R047167","article-title":"The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.","volume":"55","author":"Shayman","year":"2014","journal-title":"J. Lipid Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jchemneu.2004.02.006","article-title":"The unfolded protein response\u2013a stress signaling pathway of the endoplasmic reticulum.","volume":"28","author":"Shen","year":"2004","journal-title":"J. Chem. Neuroanat."},{"key":"B121","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbrc.2011.10.038","article-title":"Proteasome inhibitors improve the function of mutant lysosomal alpha-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation.","volume":"415","author":"Shimada","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B122","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/8904_2014_345","article-title":"Proteasome inhibitor bortezomib enhances the activity of multiple mutant forms of Lysosomal \u03b1-Glucosidase in pompe disease.","volume":"18","author":"Shimada","year":"2015","journal-title":"JIMD Rep."},{"key":"B123","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.cmet.2011.04.004","article-title":"Autophagy in the cellular energetic balance.","volume":"13","author":"Singh","year":"2011","journal-title":"Cell Metab."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/hmg\/ddt052","article-title":"TFEB regulates lysosomal proteostasis.","volume":"22","author":"Song","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B125","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/mt.2010.299","article-title":"Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder.","volume":"19","author":"Spampanato","year":"2011","journal-title":"Mol. Ther."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/jnr.23762","article-title":"New therapeutic approaches for krabbe disease: the potential of pharmacological chaperones.","volume":"94","author":"Spratley","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1542\/peds.2008-0635","article-title":"Lysosomal storage disorders in the newborn.","volume":"123","author":"Staretz-Chacham","year":"2009","journal-title":"Pediatrics"},{"key":"B128","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease.","volume":"287","author":"Sun","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B130","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2183\/pjab.90.145","article-title":"Emerging novel concept of chaperone therapies for protein misfolding diseases.","volume":"90","author":"Suzuki","year":"2014","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ymgme.2012.02.012","article-title":"Therapeutic chaperone effect of N-octyl 4-epi-beta-valienamine on murine G(M1)-gangliosidosis.","volume":"106","author":"Suzuki","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"B132","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/mt.2012.263","article-title":"A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.","volume":"21","author":"Takai","year":"2013","journal-title":"Mol. Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"729","DOI":"10.4161\/auto.5.5.8525","article-title":"The values and limits of an in vitro model of Pompe disease: the best laid schemes o\u2019 mice an\u2019 men.","volume":"5","author":"Takikita","year":"2009","journal-title":"Autophagy"},{"key":"B134","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/106002808201600503","article-title":"Diltiazem: a review of its clinical efficacy and use.","volume":"16","author":"Tartaglione","year":"1982","journal-title":"Drug Intell. Clin. Pharm."},{"key":"B135","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molcel.2004.08.029","article-title":"GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis.","volume":"15","author":"Tessitore","year":"2004","journal-title":"Mol. Cell."},{"key":"B136","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1177\/1947601910383011","article-title":"The unfolded protein response, degradation from the endoplasmic reticulum, and cancer.","volume":"1","author":"Tsai","year":"2010","journal-title":"Genes Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.1201396","article-title":"Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis.","volume":"332","author":"Tsaytler","year":"2011","journal-title":"Science"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.12.845","article-title":"First proteasome inhibitor approved for multiple myeloma.","volume":"95","author":"Twombly","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"B139","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/10408360390247832","article-title":"Carrier testing for autosomal-recessive disorders.","volume":"40","author":"Vallance","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"B141","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2141.2004.05293.x","article-title":"Lysosomal storage disorders.","volume":"128","author":"Vellodi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/jcp.21676","article-title":"Chaperone-mediated autophagy is defective in mucolipidosis type IV.","volume":"219","author":"Venugopal","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","article-title":"Common and uncommon pathogenic cascades in lysosomal storage diseases\u2217.","volume":"285","author":"Vitner","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation.","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"B145","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.chembiol.2011.04.008","article-title":"Lacidipine remodels protein folding and Ca 2+ homeostasis in Gaucher\u2019s disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase.","volume":"18","author":"Wang","year":"","journal-title":"Chem. Biol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"43454","DOI":"10.1074\/jbc.M111.274332","article-title":"Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases.","volume":"286","author":"Wang","year":"","journal-title":"J. Biol. Chem."},{"key":"B147","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.04.002","article-title":"Using pharmacological chaperones to restore proteostasis.","author":"Wang","year":"2014","journal-title":"Pharmacol. Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jpeds.2004.01.049","article-title":"Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care.","author":"Wilcox","year":"2004","journal-title":"J. Pediatr."},{"key":"B149","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1042\/bst0280150","article-title":"The molecular basis of lysosomal storage diseases and their treatment.","volume":"28","author":"Winchester","year":"2000","journal-title":"Biochem. Soc. Trans."},{"key":"B150","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/siny.2001.0088","article-title":"Lysosomal disorders.","volume":"7","author":"Wraith","year":"2002","journal-title":"Semin. Neonatol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.paed.2010.08.012","article-title":"Lysosomal disorders.","volume":"21","author":"Wraith","year":"2011","journal-title":"Paediatr. Child Health"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1172\/JCI26373","article-title":"Endoplasmic reticulum stress: cell life and death decisions.","volume":"115","author":"Xu","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B153","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1073\/pnas.1221046110","article-title":"Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B154","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1073\/pnas.1321341111","article-title":"Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.","volume":"111","author":"Yang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ejhg.2009.19","article-title":"Segregation analysis in a family at risk for the Maroteaux-Lamy syndrome conclusively reveals c.1151G>A (p.S384N) as to be a polymorphism.","volume":"17","author":"Zanetti","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"key":"B156","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj3480621","article-title":"Characterization of beta-galactosidase mutations Asp332\u2013>Asn and Arg148\u2013>Ser, and a polymorphism, Ser532\u2013>Gly, in a case of GM1 gangliosidosis.","author":"Zhang","year":"2000","journal-title":"Biochem. J."},{"key":"B157","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0092-8674(00)81588-3","article-title":"Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1.","volume":"94","author":"Zou","year":"1998","journal-title":"Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00448\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T18:49:49Z","timestamp":1602442189000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00448\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,7]]},"references-count":157,"alternative-id":["10.3389\/fphar.2017.00448"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00448","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,7]]},"article-number":"448"}}